Skip to main content
Equibles
OLMA logo

OLMA · Olema Pharmaceuticals, Inc.

Track OLMA — free Ask ALVIS about OLMA
$11.58 -0.18 (-1.53%) At close · Aug 5
Going-concern doubt — flagged May 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future. In addition, we may be unable to continue as a going concern over the long term.”
View the 10-Q filed May 12, 2026
Market Cap
$985.28M
Shares
87.35M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$11.58 Open$11.82 Day$11.43–11.97 52W$4.47–36.26 Avg vol 30d1.4M Short int15.1M · 17.3% float · 11.3d Short vol59% Last earningsMay 26, 2026 DataNov 2020–Aug 2026 Filing10-Q · May 12

Up next

Next earnings call
Jun 4, 2027 Est · unconfirmed · in 43 wks
FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed May 12, 2026

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.46
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg −34%
below
Price vs 50-day avg +2%
above
RSI (14) 49
neutral
MACD trend Negative
52-week position 22%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −6%
trailing
6-month return −51%
trailing
YTD return −54%
this year
Relative strength −62%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $11 › 200d $17 — 200d above 50d
Institutional flow Distributing
37 of 201 funds reported for Jun 30 · net -2.1M sh shares · +2 new
Insider flow Distributing
Net -$291.2K over 90 days · 100% sells
Short interest Rising
17.29% of float · ▲ +7.6% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
201 holders — near 3-yr high, broad support
Squeeze score 75
high risk · 0–100
Fundamentals
Strong
EPS growth +15%
Y/Y
Free cash flow $-146.9M
Balance sheet $48.3M
net cash
Quant / Vol
risk profile
Very High
Volatility 160%
annualized · 1-yr
Max drawdown −74%
past year
ATR 5.9%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−34% Bearish
Price vs 50-day avg
+2% Bullish
RSI (14)
49 Neutral
MACD trend
Negative Bearish
52-week position
22% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 3 of 6
Trend (MA cross) No cross
50d $11 › 200d $17 — 200d above 50d
Institutional flow Distributing
37 of 201 funds reported for Jun 30 · net -2.1M sh shares · +2 new
Insider flow Distributing
Net -$291.2K over 90 days · 100% sells
Short interest Rising
17.29% of float · ▲ +7.6% MoM · 11.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
201 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $4 Now $12 · 22% 52-wk high $36
vs 200-day avg -34% vs 50-day avg +2%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from its earnings releases, calls, and filings
Metric Latest Period YoY
gross proceeds from follow-on public offering $218.5M the fourth quarter and full year 2025 —

Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
OLMA
Olema Pharmaceuticals, Inc.
this stock
$985.28M -53.7% — — 17.3%
ONC
BeOne Medicines Ltd.
 $453.48B +7.8% +22179.2% 697.3 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $119.47B +6.9% +46.2% 27.5 2.0%
REGN
Regeneron Pharmaceuticals, Inc.
 $78.17B -0.2% +20.8% 18.8 3.4%
ARGX
Argenx SE
 $54.30B +3.2% — — 2.5%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
195
% held
116.9%
Reported
37 of 201
Top holder
FMR LLC
Held Float
View
Held by Funds
Fund positions
214
View
Short & Settlement
Short Interest Rising
Shares short
15.1M
Days to cover
11.3d
Change
+1.1M sh
View
Short Volume
Short vol %
59%
As of
Aug 5, 2026
Short Total
View
Fails to Deliver
FTD shares
1
Value
$12
As of
Jul 13, 2026
View
Off-Exchange
Off-exchange %
38.2%
Week of
Jun 29, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$291.2K
Buyers / Sellers
0 / 1
Buyers Sellers
View
Financials
Financials
Net income (FY)
$-162.5M
EPS diluted
$-1.87
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Jun 30, 2026
This year
14
View
Proposed Sales
Value
$146.4K
Shares
12.5K
Filed
Jul 24, 2026
View
Exempt Offerings
Offering
$250.0M
Filed
Dec 12, 2024
View
Earnings & Events
Earnings Calls
Last call
Jun 9, 2026
View
Investor Relations
Latest news
Olema Oncology Reports Inducement…
Published
Aug 4, 2026
View

Performance

5D 20D 120D MTD YTD
OLMA +3.5% -5.6% -51.0% +1.1% -53.7%
SPY +5.5% +3.3% +11.3% +3.1% +12.9%
vs SPY -2.0% -8.9% -62.3% -1.9% -66.6%
Key facts CIK 1750284 CUSIP 68062P106 13F (30d) 29 filings 29 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)